Morgan Stanley Sticks to Their Buy Rating for BioNTech SE (BNTX)

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE today and set a price target of $134.00.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Flynn is a 5-star analyst with an average return of 11.7% and a 60.47% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Bristol-Myers Squibb, and Pfizer.

In addition to Morgan Stanley, BioNTech SE also received a Buy from Citi’s Geoff Meacham in a report issued on January 30. However, on February 2, TipRanks – xAI reiterated a Hold rating on BioNTech SE (NASDAQ: BNTX).

Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.